Study guide
14.2 Central Nervous System Procedures
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
14.2 Central Nervous System Procedures
Key Takeaways Explain This Topic AI
Brain death flow studies demonstrate absence of intracranial arterial perfusion (hot-nose pattern teaching) using Tc-99m agents with bolus technique and correct FOV from carotids through skull vertex
Brain perfusion SPECT uses Tc-99m HMPAO (exametazime) or ECD (bicisate); acetazolamide (Diamox®) challenge assesses cerebrovascular reserve versus baseline
DaTscan® (I-123 ioflupane) images presynaptic dopamine transporters; hold interfering meds, block thyroid with iodine/perchlorate per protocol, and image at the correct delay
Cisternography, CSF leak, and shunt-patency studies use In-111 DTPA (or lab-specific agents) with timed planar/SPECT imaging along CSF pathways
Amyloid PET and ictal/interictal SPECT or PET support dementia and epilepsy workups—timing relative to seizure onset and tracer choice is critical
Last updated: August 2026
14.2 Central Nervous System Procedures
Quick Answer: Brain death = no intracranial flow. HMPAO/ECD SPECT ± acetazolamide = perfusion and reserve. DaTscan = dopamine transporter imaging with med holds . In-111 DTPA = cisternogram / leak / shunt. Amyloid PET and ictal/interictal SPECT-PET = dementia and epilepsy pathways. Prep and timing dominate pass-rate items.
Brain Flow and Brain Death Scintigraphy
Nuclear brain-death flow is an ancillary test when ordered. Inject a bolus of a lipophilic Tc-99m agent retained in viable brain ( HMPAO or ECD ), or use a flow-only approach per lab (some use DTPA). Acquire dynamic anterior flow from carotids through the calvarium, then statics (anterior, lateral, sometimes posterior).
- Pattern (teaching) Meaning
- No intracranial arterial phase Consistent with absent cerebral perfusion when technically adequate
- “Hot nose” External carotid flow without intracranial perfusion—classic teaching sign, not standalone criteria
- Clear hemispheric HMPAO/ECD uptake Perfusion present—does not support brain death
Tech non-negotiables: true bolus, FOV including neck vessels and whole brain, no infiltrate, adequate counts. A weak bolus can falsely suggest no flow. Follow institutional checklist exactly.
Brain Perfusion SPECT (HMPAO / ECD)
Tc-99m HMPAO (exametazime) and Tc-99m ECD (bicisate) cross the blood–brain barrier proportional to regional blood flow and are retained for delayed SPECT. Adult activity often ~15–30 mCi class. Quiet, dim environment before/after injection reduces activation artifacts; start SPECT after agent-specific uptake (~30–90 min class—SOP).
- Topic Teaching points
- Indications Dementia patterns, stroke/TIA, trauma, epilepsy (ictal timing)
- SPECT/CT AC and localization; check co-registration
Tumor / viability Brain FDG PET or perfusion SPECT may help viable tumor vs necrosis—FOV/prep differ from whole-body FDG
Minimize head motion (chin strap, cushion); reconstruct per lab filters.
Acetazolamide (Diamox®) Challenge
Acetazolamide is a carbonic anhydrase inhibitor that normally increases cerebral blood flow. After baseline SPECT (or in a two-day protocol), inject acetazolamide (classic adult teaching ~1 g IV over minutes—follow order), then inject the perfusion tracer at the protocol interval and reimage.
- Result concept Teaching
- Global increase Intact cerebrovascular reserve
Regions that fail to augment or relatively worsen Compromised reserve (e.g., severe stenosis/Moyamoya teaching)
Contraindications/cautions: sulfa allergy discussion, severe renal/hepatic disease, electrolyte issues—defer to the authorized user/protocol. Hydrate; warn about transient flushing/paresthesias.
DaTscan® (I-123 Ioflupane)
I-123 ioflupane binds presynaptic dopamine transporters in the striatum. Used to help distinguish essential tremor from Parkinsonian syndromes (not to stage all movement disorders alone).
- Protocol element Tech action
- Thyroid blockade Stable iodine or perchlorate per package insert/SOP before dose
- Activity Often ~3–5 mCi class IV (follow insert)
- Uptake delay Image commonly 3–6 hours post-injection
- Acquisition SPECT (often with CT) centered on striata; immobilization critical
Medication holds Many stimulants, certain antidepressants, and other drugs interfere— pharmacy/neurology med review days before (lab list)
Trap: imaging too early, motion, and unblocked thyroid (though primary issue is med interference and positioning). Normal “comma” vs abnormal “period” striatal shape is physician pattern language—you deliver motion-free, timed, med-reconciled data.
CSF Studies: Cisternogram, Leak, and Shunt Patency
In-111 DTPA (common) is injected intrathecally (usually lumbar) by a qualified physician under sterile technique—not a standard peripheral IV skill for this indication. Image at timed points (e.g., 2–4–6–24–48–72 h per protocol) of spine and head.
Study goal What you image / look for (tech level)
Cisternogram (NPH workup teaching) Ascent over convexities vs early ventricular reflux/persistence patterns per physician criteria
CSF leak Pledgets in nasal cavity ± imaging; assay pledgets in well counter; compare to plasma
Shunt patency Inject into reservoir/shunt system as directed; image pathway of flow into peritoneum or distal site
Tech points: absolute asepsis, correct energy windows for In-111 (171 and 245 keV), medium-energy collimators, and meticulous labeling of pledgets (left/right, site). Leak studies fail if pledgets are mishandled or timing is wrong.
Amyloid PET
Florbetapir, florbetaben, flutemetamol (F-18 amyloid agents) bind cortical β-amyloid plaques. Prep is agent-specific (often less fasting than FDG). Inject, wait the prescribed uptake (commonly ~30–90 min class), then PET/CT brain. Patient must hold still; motion ruins cortical-to-cerebellar interpretation. Know this is not FDG—different biology and read criteria (binary positive/negative frameworks in labeling).
Epilepsy: Ictal vs Interictal
Mode Tracer examples Timing concept
Ictal SPECT HMPAO/ECD injected at seizure onset Hyperperfusion of epileptogenic zone if injection is truly ictal
Interictal SPECT/PET HMPAO/ECD or FDG PET Hypoperfusion/hypometabolism in chronic focus
Team sport: EEG monitoring unit, rapid injection kit at bedside, stopwatch documentation of injection vs clinical/EEG onset. Late injection becomes post-ictal and can mislocalize. Transport for SPECT after stabilization; co-register to MRI when available.
CNS Prep and Timing Snapshot
- Procedure Critical prep / timing
- Brain death flow Bolus + full head/neck FOV
- Perfusion SPECT Quiet room; agent-specific delay
- Diamox Baseline vs challenge schedule; med history
- DaTscan Med holds; thyroid block; 3–6 h image
- CSF studies Intrathecal sterility; multi-day imaging
- Amyloid PET Agent delay; still head
- Ictal SPECT Inject at onset—document seconds
Master which tracer, which route, which clock . That triad covers most CNMT CNS clinical items.